Schaeffers Research
26 Aug 2026, 18:48 UTC · 8w ago
Novavax Stock Pulls Back After Milestone Vaccine Success
Impact · against what's priced in
The positive skin cancer vaccine trial results are already largely reflected in MRNA's premium valuation, resulting in negligible impact. NVAX faces significant near-term pressure as high short interest and a surge in put buying suggest institutional skepticism despite the clinical success.
- MRNA+0.00
Already priced in
- The price assumes
The price fully reflects the Phase 3 INT cancer vaccine demonstrating a statistically significant survival benefit
The market is already paying for a successful oncology pipeline to justify its 137% premium over median analyst targets; positive results for the skin cancer vaccine simply confirm what the current price assumes.
What MRNA's price assumes · Aug 26
